Leptin Receptor Lys656Asn Polymorphism Is Associated with Decreased Leptin Response and Weight Loss Secondary to a Lifestyle Modification in Obese Patients

2006 ◽  
Vol 37 (7) ◽  
pp. 854-859 ◽  
Author(s):  
Daniel de Luis Roman ◽  
Rocio Aller de la Fuente ◽  
Manuel Gonzalez Sagrado ◽  
Olatz Izaola ◽  
Rosa Conde Vicente
Keyword(s):  
Weight Loss ◽  
Leptin Receptor ◽  
Lifestyle Modification ◽  
Obese Patients

Obesity Therapy: How and Why?

2020 ◽  
Vol 27 (2) ◽  
pp. 174-186 ◽  
Author(s):  
Sara Paccosi ◽  
Barbara Cresci ◽  
Laura Pala ◽  
Carlo Maria Rotella ◽  
Astrid Parenti
Keyword(s):  
Weight Loss ◽  
Lifestyle Modification ◽  
Herbal Medicines ◽  
The Internet ◽  
Obese Patients ◽  
Self Medication ◽  
Pharmacological Management ◽  
Regulatory Standards ◽  
Meta Analyses ◽  
Obesity Drugs

Background: Obesity represents the second preventable mortality cause worldwide, and is very often associated with type 2 Diabetes Mellitus (T2DM). The first line treatment is lifestyle modification to weight-loss, but for those who fail to achieve the goal or have difficulty in maintaining achieved results, pharmacological treatment is needed. Few drugs are available today, because of their side effects. Objective: We aim to review actual pharmacological management of obese patients, highlighting differences between Food and Drug Administration - and European Medicine Agency-approved molecules, and pointing out self-medications readily obtainable and widely distributed. Methods: Papers on obesity, weight loss, pharmacotherapy, self- medication and diet-aid products were selected using Medline. Research articles, systematic reviews, clinical trials and meta-analyses were screened. Results: Anti-obesity drugs with central mechanisms, such as phentermine and lorcaserin, are available in USA, but not in Europe. Phentermine/topiramate and naltrexone/bupropion combinations are now available, even though the former is still under investigation from EMA. Orlistat, with peripheral mechanisms, represents the only drug approved for weight reduction in adolescents. Liraglutide has been approved at higher dose for obesity. Anti-obesity drugs, readily obtainable from the internet, include crude-drug products and supplements for which there is often a lack of compliance to national regulatory standards. Conclusion: Mechanisms of weight loss drugs include the reduction of energy intake or the increase in energy expenditure and sense of satiety as well as the decrease of hunger or the reduction in calories absorption. Few drugs are approved, and differences exist between USA and Europe. Moreover, herbal medicines and supplements often sold on the internet and widely used by obese patients, present a risk of adverse effects.

scholarly journals A contemporary view on obesity treatment in adults

2021 ◽  
pp. 45-50
Author(s):  
V.I. Velychko ◽  
B.M. Mankovskyi ◽  
T.F. Tatarchuk ◽  
D.O. Lahoda ◽  
I.M. Todurov ◽  
...  
Keyword(s):  
Weight Loss ◽  
Body Fat ◽  
Lifestyle Modification ◽  
Obesity Treatment ◽  
Pharmacological Therapy ◽  
Overweight And Obesity ◽  
Evidence Based ◽  
Obese Patients ◽  
Lifestyle Modifications

Today, the prevalence of overweight and obesity is pandemic. This disorder is defined as “a complex chronic disease in which abnormal or excess body fat impairs health, increases the risk of long-term medical complications, and decreases life expectancy”.This article presents evidence-based clinical guidelines for the management of obese patients, as well as excerpts comments on pharmacological treatment.Treatment approaches for overweight and obese patients include behavioral interventions, lifestyle adjustments, etc. One of the methods is pharmacological therapy, based on the following principles: therapy for weight loss can be used starting already at a body mass index ≥ 27 kg/m2 or ≥ 30 kg/m2 with complications associated with excess body fat. As drugs can be used liraglutide, combination of naltrexone + bupropion, orlistat. Pharmacotherapy must be accompanied by lifestyle modification, including if necessary therapeutic diet, increased physical activity on ongoing basis with its mandatory control, and behavioral or cognitive-behavioral therapy. Pharmacotherapy can be used to support the weight loss achieved through lifestyle modifications and to prevent weight gain. It is forbidden to use over-the-counter drugs unless they are approved for weight control. Patients with metabolic obesity should be consulted by specialists to assess the feasibility of bariatric surgery, followed by treatment with this specialist.Every clinician must have sufficient knowledge to diagnose obesity and offer their patients an individualized, long-term, evidence-based weight loss regimen. The success of obesity treatment depends on the patient's trust the doctor and on the doctor's knowledge in this area.

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

2018 ◽  
Author(s):  
Clément K ◽  
Biebermann H ◽  
Farooqi IS ◽  
Van der Ploeg L ◽  
Wolters B ◽  
...  
Keyword(s):  
Weight Loss ◽  
Leptin Receptor
Sign in / Sign up

Export Citation Format

Share Document